John Stanford

John Stanford, host of the Making Medicines podcast, brings his insights on biotech policy from Washington, DC. He discusses the National Defense Authorization Act and its implications, highlighting biotech as a national security asset. Rising valuations and an optimistic outlook for IPOs in 2026 are also covered. Other highlights include data from ASH on various treatments, including CAR-T therapies and Dyne's DMD candidate. The conversation wraps up with predictions and optimism levels for the biotech sector's future.